This morning, Hutchison China MediTech has announced the initiation of a Phase I clinical trial of its novel Syk (spleen tyrosine kinase) inhibitor HMPL-523 in patients with haematological malignancies (i.e. blood cancers) in China. We see today’s news as reflecting the continued momentum of Chi-Med’s pipeline into the clinic, executed in line-with expected timeframes. We make no change at this point to our recommendation or investment thesis but we remind investors to continue to
